91807-29-3

Basic information

• Product Name: N-(4-aminophenyl)-4-methoxybenzenesulfonamide
• Synonyms: N-(4-aminophenyl)-4-methoxybenzenesulfonamide
• CAS NO: 91807-29-3
• Molecular Weight: 278.332
• Mol File: 91807-29-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(4-aminophenyl)-4-methoxybenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-aminophenyl)-4-methoxybenzenesulfonamide(91807-29-3)
• EPA Substance Registry System: N-(4-aminophenyl)-4-methoxybenzenesulfonamide(91807-29-3)

Safety Data

• Hazardous Substances Data: 91807-29-3(Hazardous Substances Data)

Upstream product

• 100-01-6 4-nitro-aniline 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 21226-36-8 4-Methoxy-benzolsulfonsaeure-<4-nitro-anilid> 
• 106-50-3 1,4-phenylenediamine 

Downstream Products

• 1030598-45-8 C₂₂H₁₈F₆N₂O₃S 

Relevant articles and documents

Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer

The family with sequence similarity 20, member C (Fam20C), a Golgi casein kinase, has been recently regarded as a potential therapeutic target for the treatment of triple negative breast cancer (TNBC). Lacking enzyme activity center has been becoming an obstacle to the development of small-molecule inhibitors of Fam20C. Herein, we combined in silico high-throughput screening with chemical synthesis methods to obtain a new small-molecule Fam20C inhibitor 3r, which exhibited desired anti-proliferative activities against MDA-MB-231 cells and also inhibited migration. Subsequently, the enzymatic assay, molecular docking, and molecular dynamics (MD) simulations were carried out for validating that 3r could bind to Fam20C. In addition, 3r was found to induce apoptosis via the mitochondrial pathway in MDA-MB-231 cells as well as to inhibit cell migration. Moreover, we demonstrated that 3r inhibited tumor growth in vivo and thereby having a good therapeutic potential on TNBC. Taken together, these results suggest that 3r may be a novel Fam20C inhibitor with anti-proliferative and apoptosis-inducing activities, which would shed light on discovering more small-molecule drugs for the future TNBC therapy.

Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity

A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK). Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100?nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10?μM, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells). Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner. In addition, it almost completely induced the apoptosis at a concentration of 10?μM. Compound 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer.